NCT06452342View on ClinicalTrials.gov

TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Venous ThromboembolismVenous ThrombosesHeavy Menstrual BleedingAnticoagulants and Bleeding Disorders

Interventions

DRUG

Tranexamic acid

Tranexamic acid 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period

OTHER

No Tranexamic acid

Routine clinical care without Tranexamic acid

All Listed Sponsors

collaborator

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

NETWORK

lead

University Health Network, Toronto

OTHER

NCT06452342 - TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study | Biotech Hunter | Biotech Hunter